Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

235989

Sigma-Aldrich

Brij® L4

average Mn ~362

Synonyme(s) :

Polyethylene glycol dodecyl ether, Polyoxyethylene (4) lauryl ether

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule linéaire :
(C20H42O5)n
Numéro CAS:
9002-92-0
Numéro MDL:
MFCD00043063
Code UNSPSC :
12161900
ID de substance PubChem :
24854130
Nomenclature NACRES :
NA.21

Description

non-ionic

Niveau de qualité

200

Poids mol.

average Mn ~362

Indice de réfraction

n20/D 1.451 (lit.)

Densité

0.95 g/mL at 25 °C (lit.)

HLB

9

Chaîne SMILES 

CCCCCCCCCCCCOCCOCCOCCOCCO

InChI

1S/C20H42O5/c1-2-3-4-5-6-7-8-9-10-11-13-22-15-17-24-19-20-25-18-16-23-14-12-21/h21H,2-20H2,1H3

Clé InChI

WPMWEFXCIYCJSA-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

Brij® L4 is a non-ionic surfactant. It comprises an alkyl (C12) tail attached to an oxyethylene headgroup.

Application

Brij® L4 has been used:
  • as a surfactant for the synthesis of copper(I) oxide (Cu2O) spherical nanoparticles using a microemulsion technique
  • as a non-ionic surfactant for preparing reverse micelles to synthesize Pt3Co alloy nanoparticles
  • as a surfactant to enhance the efficiency of interfacial coupling of hydrophobic materials and to make hydrogel

Actions biochimiques/physiologiques

Brij® L4 exhibits amphiphilic properties. Brij L4 contains hydrophobic and hydrophilic regions that can form micelles and disperse hydrophobic drugs into the core of micelles. This in turn enhances drug solubility. Brij L4 also elicits a strong inhibitory effect against breast cancer resistance protein (BCRP) mediated drug efflux. It inhibits Taq adsorption better when compared to other commonly used surfactants. Brij L4 supports droplet polymerase chain reaction (PCR) in picoliter reaction volumes at standard Taq concentrations.

Informations légales

Brij is a registered trademark of Croda International PLC

Pictogrammes

Exclamation markEnvironment
GHS07,GHS09

Mention d'avertissement

Warning

Mentions de danger

H302,H315,H319,H411

Classification des risques

Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Skin Irrit. 2

Code de la classe de stockage

10 - Combustible liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Gloves

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
MKCQ7698
MKCL6849
MKCK4613
MKCH6859
MKCD2308

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 7

1 of 7

USP

USP

1372468

Polyoxyl 23 lauryl ether

Brij® L23 suitable for Stein-Moore chromatography

Sigma-Aldrich

P1254

Brij® L23

Brij® S20

Sigma-Aldrich

P4019

Brij® S20

Brij® 58 average Mn ~1124

Sigma-Aldrich

P5884

Brij® 58

Decaethylene glycol mono­dodecyl ether nonionic surfactant

Sigma-Aldrich

P9769

Decaethylene glycol mono­dodecyl ether

Thesit® for membrane research

Sigma-Aldrich

88315

Thesit®

Brij® O10

Sigma-Aldrich

P6136

Brij® O10

Darío Morais et al.
Rhinology, 50(1), 80-86 (2012-04-04)
Hereditary Haemorrhagic Telangiectasia or Rendu-Osler-Weber syndrome is a rare autosomal dominant vascular disease characterized by mucocutaneous and gastrointestinal telangiectases and localized arteriovenous malformations in lung, brain and liver. Epistaxis, due to rupture of telangiectases of the nasal mucosa, is the
N Shadid et al.
The British journal of surgery, 99(8), 1062-1070 (2012-05-26)
New minimally invasive treatment modalities, such as ultrasound-guided foam sclerotherapy (UGFS), are becoming more popular. In a multicentre randomized controlled non-inferiority trial, the effectiveness and costs of UGFS and surgery for treatment of the incompetent great saphenous vein (GSV) were
B McAree et al.
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 43(6), 721-725 (2012-04-18)
To compare the half-life of STD and polidocanol air-based foams and the damage they inflict upon human great saphenous vein in an in-vitro model. The time for the volume of 3% STD and polidocanol foams to reduce by 10% (T(90))
L Lund et al.
The Journal of urology, 191(5), 1347-1350 (2013-11-23)
We evaluate whether aspiration and sclerosing of hydrocele testis is an effective treatment. Men with symptomatic hydrocele testis were included in this prospective, double-blind, randomized study with polidocanol and placebo. Patients were randomized to active treatment or placebo at the
Alessandro Frullini et al.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 38(5), 741-747 (2012-05-01)
Foam sclerotherapy has been proven to be a safe and effective treatment for superficial venous insufficiency, but transient visual and neurologic disturbances continue to be reported. These side effects have been theorized to be related to the presence of air
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique